1 / 1

Cardiac Function Test Results in Phase III Trial of Lapatinib and Capecitabine for Metastatic Breast Cancer

This study evaluates the cardiac function of patients in a Phase III trial investigating lapatinib plus capecitabine for treating HER2-positive metastatic breast cancer. Findings demonstrate the impacts of these drugs on cardiac health, highlighting the importance of monitoring cardiac function in patients receiving targeted therapies. The results emphasize the need for careful management of potential cardiac side effects while providing effective treatment options for advanced breast cancer.

christopher-anania
Télécharger la présentation

Cardiac Function Test Results in Phase III Trial of Lapatinib and Capecitabine for Metastatic Breast Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Figure 1 Results of cardiac function tests in the phase III trial of lapatinib plus capecitabine for metastatic breast cancer Permission obtained from Geyer CE et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733–2743 Cameron DA and Stein S (2008) Drug Insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer Nat Clin Pract Oncol doi:10.1038/ncponc1156

More Related